Powered by LiquidBiopsy, ClearID provides a minimally-invasive tool to monitor cancer patients, enabling more frequent testing and real-time molecular profiling of tumor DNA. Leveraging patented cell enrichment technology, the test analyzes patients' individual mutations to match them with targeted cancer therapies and clinical trials.